A carregar...
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872175/ https://ncbi.nlm.nih.gov/pubmed/27247757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716636541 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|